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ARTICLE
An engineered human Fc domain that behaves
like a pH-toggle switch for ultra-long circulation
persistence
Chang-Han Lee 1,14, Tae Hyun Kang 1,13,14, Ophélie Godon2, Makiko Watanabe 1, George Delidakis 1,
Caitlin M. Gillis 2, Delphine Sterlin2, David Hardy3, Michel Cogné4, Lynn E. Macdonald5,
Andrew J. Murphy 5, Naxin Tu5, Jiwon Lee 6, Jonathan R. McDaniel1, Emily Makowski7, Peter M. Tessier8,9,
Aaron S. Meyer 10, Pierre Bruhns2,15* & George Georgiou1,11,12,15*
The pharmacokinetic properties of antibodies are largely dictated by the pH-dependent
binding of the IgG fragment crystallizable (Fc) domain to the human neonatal Fc receptor
(hFcRn). Engineered Fc domains that confer a longer circulation half-life by virtue of more
favorable pH-dependent binding to hFcRn are of great therapeutic interest. Here we devel-
oped a pH Toggle switch Fc variant containing the L309D/Q311H/N434S (DHS) substitu-
tions, which exhibits markedly improved pharmacokinetics relative to both native IgG1 and
widely used half-life extension variants, both in conventional hFcRn transgenic mice and in
new knock-in mouse strains. engineered specifically to recapitulate all the key processes
relevant to human antibody persistence in circulation, namely: (i) physiological expression of
hFcRn, (ii) the impact of hFcγRs on antibody clearance and (iii) the role of competing
endogenous IgG. DHS-IgG retains intact effector functions, which are important for the
clearance of target pathogenic cells and also has favorable developability.
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IgG isotype antibodies avoid clearance by endolysosomaldegradation by virtue of their pH-dependent binding to theneonatal Fc receptor (FcRn), which is expressed by cells in
nearly every organ in mammals1–3. The FcRn receptor consists of
the glycosylated heavy α-chain polypeptide, an MHC I class
family member which associates with β2-microglobulin (β2m)4,5.
IgG internalized by pinocytosis binds to FcRn at endosomal pH
(5.5–6.0) and as a result, instead of being directed to the endo-
lysosomal compartment for degradation, IgG:FcRn complexes are
sorted into tubules originating from sorting endosomes and
directed to return to the plasma membrane. Upon fusion with the
plasma membrane, the intracellular fluid within the tubules is
released and rapidly equilibrates with the extracellular pH 7.4
(refs. 6–8). At extracellular pH, the affinity of FcRn for the Fc
domain is so low that antibodies are released back into circula-
tion. This process occurs readily, despite the strong avidity effects
of both the high local concentration of FcRn at the site of vesicle
fusion, and the 2:1 stoichiometric binding of FcRn to IgG9,10.
Biophysical studies have elucidated the molecular details of the
IgG:FcRn interaction including the role of residues in the
CH2–CH3 interface of the Fc domain in contact with FcRn,
the pivotal role of His310 and His435 on pH-dependent binding,
and the significance of protein dynamics11–13.
Engineering the human Fc domain to improve pharmacoki-
netic (PK) properties (manifest as an increased area under the
plasma drug concentration–time curve (AUC), a lower clearance
rate and a longer β-phase T1/214,15) is of great interest for ther-
apeutic purposes3,16–20. Better PK enable less frequent adminis-
tration and lower dosing, which in turn translate into improved
patient compliance and lower costs. Mutations of the Fc domain
that enhance the affinity for FcRn at both the endosomal and
physiological pH have been shown to result in greater antibody
clearance. In contrast, Fc mutations that preferentially enhance
FcRn affinity at pH 5.8 confer increased antibody half-life in
circulation16,18,20–23. Fc domains containing the amino acid
substitutions M428L/N434S (LS mutant), M252Y/S254T/T256E
(YTE mutant), or H433K/N434F (KF mutant) confer 10- to 12-
fold higher affinity for FcRn at pH 5.8, result in the greatest
reported increase in antibody half-life (2- to 4-fold in circulation)
in mice and in non-human primates, and are currently being
evaluated in multiple clinical trials16,24–26. Notably, ravulizumab,
a complement C5-inhibiting antibody containing the LS muta-
tions, was FDA-approved for paroxysmal nocturnal hemoglobi-
nuria and shown to have a serum half-life of ~49.7 days27, and
MEDI8897, a respiratory syncytial virus (RSV)-neutralizing
antibody containing the YTE mutations, was shown to have a
serum half-life of ∼70 days, compared to approximately 20 days
for wild-type (wt) IgG1, in infants in a phase 1b/2a study for
prophylaxis against RSV infection28.
While further improvements in human antibody PK are highly
desirable, extensive protein engineering campaigns focused on
identifying mutations that confer even higher affinity for FcRn at
pH 5.8 relative to the YTE or LS Fc variants have so far failed to
yield amino acid combinations capable of imparting even longer
circulation half-life in animal models20,23,29–31. Notably, YTE-
and LS-Fc domains have significant binding to FcRn at pH 7.4
under high avidity conditions11. Residual binding at pH 7.4 may
have a negative effect on plasma recycling and circulation
persistence32,33. Another key consideration in the engineering of
antibodies with ultra-long circulation half-life is that any muta-
tion introduced into the Fc domain should not negatively impact
other antibody characteristics such as effector functions or
manufacturability34. For example, the YTE, LS, and KF mutations
reduce FcγR binding and effector functions to various degrees
(depending on the mutant antibody and patient FcγR allotype),
and the YTE mutations have been reported to also reduce
complement-dependent cytotoxicity (CDC)18,35.
Antibody PK are routinely evaluated in transgenic (Tg) mice
overexpressing human FcRn (hFcRn) from non-native
promoters36,37. However, the currently available hFcRn Tg
mouse models do not recapitulate many of the mechanisms that
affect antibody clearance. Key limitations of the existing mouse
models used for antibody PK studies arise from: (i) non-
physiological levels of transgene hFcRn expression relative to
mouse FcRn in wild-type animals38; (ii) expression of mouse β2m
instead of human β2m (hβ2m) in many of the currently used
models36,37,39; (iii) absence of endogenously produced human IgG
to compete for hFcRn binding40; and (iv) no ability to account for
the effect of binding to human FcγRs in clearance41,42. To address
these limitations, as part of this work we constructed new knock-
in mouse models that express hFcRn, hβ2m, and hFcγRs; and, in
addition, produce endogenously chimeric mouse–human IgG1,
composed of mouse variable regions and human constant regions
for the heavy and light chain (hIgG1,κ).
Here, we report the engineering of a human IgG Fc domain
which, by virtue of having moderately higher affinity for FcRn at
pH 5.8 but no detectable binding at pH 7.4 under high avidity
conditions, confers improved antibody PK properties compared
to the clinical stage YTE and LS variants, both in the commonly
used hFcRnTg mouse model (hemizygotic 276) as well as in our
new knock-in model (hFcRn-hβ2m-hFcγRs-hIgG1,κ mice).
Importantly, we show that antibodies utilizing our engineered
ultra-long half-life Fc domain display the full range of effector
functions as the wt Fc domain while exhibiting far favorable
biophysical properties for clinical development.
Results
Pharmacokinetics properties of an engineered human Fc var-
iant. We developed a strategy that capitalizes on Escherichia coli
display of large combinatorial IgG libraries (Anchored Peri-
plasmic Expression (APEx) technology43–46) for the isolation of
clones expressing human IgG1 with mutated Fc domains that
bind selectively to the human FcRn/human β2m complex (hFcRn:
hβ2m) at pH 5.8 but not at pH 7.4 (Fig. 1a). Select regions of the
human IgG1 CH2–CH3 hinge were combinatorially mutagenized
(Supplementary Fig. 1a–c and Supplementary Table 1) to create a
library of >108 transformants. Briefly, E. coli spheroplasts
expressing mutated human IgG1 (Trastuzumab) anchored on the
external leaflet of the inner membrane were first screened by
FACS for binding to Alexa488-labeled hFcRn:hβ2m. Three
rounds of FACS with hFcRn:hβ2m at pH 5.8 were performed to
enrich antibodies with Fc domains with higher binding affinity at
pH 5.8. The pool of clones enriched for enhanced binding at
endosomal pH was then subjected to a competitive, two-step
labeling process to eliminate variants that have detectable binding
at pH 7.4 to high avidity, dimeric, GST-hFcRn:hβ2m. For this
purpose, spheroplasted cells were labeled with an excess of
Alexa647-labeled GST-hFcRn:hβ2m (red) at pH 7.4 and then
spheroplasts were washed with pH 7.4 phosphate-buffered saline
(PBS). The spheroplasts were subsequently labeled with mono-
meric hFcRn:hβ2m-Alexa488 (green) at pH 5.8, and clones with
high green fluorescence and low red fluorescence (i.e. absence of
residual Alexa647-labeled GST-hFcRn:hβ2m from the first
labeling step) were isolated and characterized (Fig. 1a). Four
clones expressing different Fc variants from the last round of
screening were isolated, individually confirmed to display pH-
dependent binding by FACS, and were all found to share three
amino acid substitutions: V264E, L309D, and Q311H (EDH)
(Supplementary Fig. 1d).
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The four isolated antibody variants were produced in HEK293
cells. One variant, EDHY-IgG1 (V264E, L309D, Q311H, and
N434Y), had a ~20-fold better affinity (KD,pH5.8= 28 nM) for
hFcRn at pH 5.8 compared to wt IgG1 (KD,pH5.8= 550 nM) but
also had residual binding at pH 7.4. A second variant, EDHS-
IgG1 (V264E, L309D, Q311H, and N434S), had a ~6-fold
increased affinity at 5.8 (KD,pH5.8= 93 nM) but no apparent
binding at pH 7.4 (Supplementary Fig. 1e–g). Very extensive
mutagenesis efforts aimed at identifying mutations conferring
even better KD,pH 5.8 were unsuccessful, as all of the mutants
isolated based on higher affinity at pH 5.8 had detectable binding
at pH 7.4 based on FACS analysis.
Antibodies with the EDHS mutations in the Fc had drastically
reduced binding to effector hFcγRs (Supplementary Fig. 1h),
which was found to be due to the V264E mutation47. Since a
V264E substitution has a minimal effect on hFcRn binding at pH
5.8 (ref. 48), it was reverted back to a valine to yield the L309D/
Q311H/N434S (DHS) Fc domain, resulting in complete recovery
of hFcγR binding (Supplementary Fig. 1h). Moreover, these three
amino acids substitutions did not affect the N-glycosylation
pattern of the Fc domain which was comparable to that of wt
IgG1 antibodies (Supplementary Fig. 2).
We performed a detailed analysis of the hFcRn:hβ2m-binding
kinetics of DHS antibodies as a function of pH using SPR analysis
with immobilized hFcRn:hβ2m at low, medium, or high density11
(500, 2000, or 4000 RUs, Fig. 1b–d and Supplementary Fig. 3).
Consistent with earlier reports49, YTE- and LS-IgG1 showed
moderate and significant binding, at pH 7.4, respectively when
SPR analysis was performed with medium or high hFcRn:hβ2m
densities (Fig. 1b, c, Table 1). In contrast, we could detect no
binding of DHS- or wt-IgG1 to hFcRn:hβ2m at physiological
conditions at even the highest density tested (Fig. 1b).
The PK of Trastuzumab, which does not bind any mouse
targets, formatted with DHS-, YTE-, LS-, or wt-IgG1 Fc domains
were first evaluated in hemizygous hFcRnTg mice (hemizygotic
Tg276), a widely used Tg mouse model for comparing the
circulation persistence of human antibodies37. Following admin-
istration of a single intravenous dose (i.v. 2 mg/kg) by tail vein
injection, the β-phase T1/2 (β-phase half-life) of DHS was 2.0- and
3.1-fold higher compared to YTE and LS variants (290.9 ± 25.6 h
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Fig. 1 Engineering a human Fc domain with optimized pH-dependent FcRn binding for ultra-long circulation persistence. a Screening strategy for the
isolation of Fc mutations that confer favorable pH-dependent FcRn-binding using E. coli display. b, c SPR binding of IgG mutants (800 nM) to hFcRn:hβ2m
immobilized at low, medium, or high density (500, 2000, and 4000 RU, respectively) either b at pH 7.4 or c as a function of pH. Normalized binding
intensity was calculated as the pH-dependent RU over the RUmax at pH 6.0, for antibodies at 800 nM. Error bars: standard deviation from three
independent experiments. d–g Serum antibody concentration of DHS formatted IgG1 (d), IgG2 (e), IgG3 (f), and IgG4 (g) antibodies in hemizygotic Tg276
hFcRn transgenic mice as a function of time after administration. Each antibody variant (2 mg/kg) was administered intravenously to hemizygous Tg276
mice (n= 11 for IgG1 and n= 5 for IgG2, IgG3, and IgG4). Antibody concentrations were determined by ELISA.. Data are presented as mean ± standard
deviation
Table 1 KD values for binding of DHS, YTE, LS variants or wt
IgG1 to hFcRn:hβ2m dimer at pH 5.8 and 7.4
KD (nM) pH 5.8 pH 7.4
Low
density
Medium
density
High
density
wt-IgG1 550 ± 50 ND ND ND
DHS-IgG1 110 ± 20 ND ND ND
YTE-IgG1 23 ± 1 ND 4730 ± 480 4290 ± 310
LS-IgG1 55 ± 3 ND 946 ± 170 567 ± 152
All IgG variants analyzed with hFcRn:hβ2m dimer and their kinetic values were analyzed by the
equivalent binding model. Data are presented as mean ± standard deviation from triplicate
experiments
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compared to 148.4 ± 36.8 and 92.9 ± 6.1 h, respectively, data are
presented as mean ± standard deviation). Total drug exposure
over time for DHS-IgG1 (AUCinf) was 1.6-, 1.9-, and 5.3-fold
greater relative to YTE-, LS-, and wt-IgG1 variants, respectively
(Fig. 1d, Table 2). Antibody clearance followed biphasic kinetics,
with a clearance rate of 0.11 ± 0.01 mL/day/kg for DHS-IgG1,
approximately 6-fold lower than wt IgG1, and 1.9- and 2.2-fold
lower than YTE- and LS-IgG1. Introduction of the DHS
mutations into the Fc domain of IgG2, IgG3 (G3m16 allotype
with H435 residue), or IgG4 subclasses also resulted in no
detectable interaction with FcRn at pH 7.4, and likewise,
conferred significantly improved PK for all the other three IgG
subclasses (Fig. 1e–g, Supplementary Fig. 4, Supplementary
Table 2). Collectively, our data: (a) reveal that the DHS Fc
domain imparts improved antibody PK properties in the
hemizygous Tg276 hFcRnTg model relative to the best in class
clinical stage, half-life extension variants YTE and LS and (b)
support the hypothesis32,33 that residual binding to FcRn at
physiological pH has a major detrimental effect on antibody
circulation persistence.
Pharmacokinetic studies in novel knock-in mouse models. To
more accurately evaluate antibody PK we constructed knock-in
(KI) mouse models that account for multiple processes known to
affect human IgG clearance and homeostasis (Fig. 2a–e). In these
KI mouse strains: (i) the hFcRn:hβ2m complex is expressed in a
manner that faithfully reflects mouse FcRn levels, (ii) the human
effector FcγR family is expressed to account for FcγR-dependent
clearance, and finally, (iii) human IgG1, which, unlike murine
IgG, competes with administered therapeutic antibodies for
hFcRn binding40, is produced endogenously. We developed a
mouse in which the murine FcγR genes had been exchanged with
the corresponding human genes, including introns and regulatory
elements for FCGR1A and for FCGR2A, FCGR2B, FCGR2C,
FCGR3A, and FCGR3B genes (hFcγRKI mouse, intercross of
VG6074 and VG1543 mice50; Fig. 2a, b)51. The Fcgrt (mouse
FcRn gene) was replaced with FCGRT (human FcRn gene,
VG1481; Fig. 2c) and the B2m (mouse β2m gene) was replaced
with B2M (human β2m gene, VG5153; Fig. 2d). The hFcRnKI
hβ2mKI hFcγRKI mice (designated as Marlene mice) were bred by
crossing the four transgenes as shown in Fig. 2e. Finally, to
account for the fact that endogenous mouse IgG does not com-
pete with human IgG for binding to human FcRn52, the heavy-
chain constant region of human IgG1 (IGHG1) was knocked-in
to replace the switch μ region of the mouse heavy-chain locus,
and the human kappa light-chain constant region (IGK) was
knocked-in to replace the mouse kappa light-chain region (kappa
light chains are used in 95% of circulating antibodies in mice),
thereby generating mice that exclusively produce human IgG1
heavy chains, predominantly associated to human kappa light
chains (Fig. 2f, g). The hFcRnKI hβ2mKI hFcγRKI hIgG1,κKI mice
(designated as Scarlett mice) were bred by crossing the Marlene
and the hIgG1,κKI mice (Fig. 2h). hFcRn expression was con-
firmed by immune-histochemistry and RT-PCR of spleens of
Scarlett mice (Fig. 2i, Supplementary Fig. 5). Cell type-specific
expression of hFcγRs in Marlene and Scarlett is reported in Fig. 2j
and Supplementary Fig. 6 is similar to that of humans, and
consistent with our earlier reported expression pattern for
hFcγRKI mice50. Scarlett mice displayed 440 ± 120 μg/mL of
human IgG1 in serum and undetectable levels of mouse IgG. The
mouse IgG serum concentration in control C57BL/6J mice was
605 ± 147 μg/mL, in the same order of magnitude as human IgG1
in Scarlett mice.
We observed very comparable β-phase elimination half-life in
the KI animals that produce endogenous human antibodies
(Scarlett) for three different approved IgG1 antibodies (Trastu-
zumab, Rituximab, or Omalizumab) after a single intravenous
dose (i.v. 2 mg/kg) by tail vein injection. Specifically, for
Trastuzumab we compared the PK between the Scarlett mice
and animals that do not have circulating human IgG1 (Marlene
mice; Supplementary Fig. 7). The β-phase elimination half-life
was 40% lower in the Scarlett mice underscoring how competi-
tion for FcRn binding by circulating human IgG1 impacts the PK
of administered antibodies in hFcRnTg mice.
Consistent with the trends observed in the hemizygous Tg276
hFcRnTg mouse model, the data in Fig. 2k and Table 3 reveal that
in Scarlett mice -DHS antibodies have ≥50% longer β-phase half-
life (P ≤ 0.0001 to LS- or YTE-IgG1), a proportional increase in
AUCinf (P ≤ 0.0001 to LS- or YTE-IgG1), and a proportional
decrease in clearance rate (P ≤ 0.0001 to LS- or YTE-IgG1)
relative to the YTE and LS variants. Compared to wt IgG1, the
DHS mutations resulted in fourfold longer β-phase half-life and
fivefold greater AUCinf.
Effector functions and biophysical properties of DHS-Fc.
Mutations that favorably impact antibody serum half-life can
adversely affect binding to effector hFcγRs, in turn impairing the
clearance of target cells by ADCC or ADCP35. Consistent with
earlier reports, SPR measurements showed that the YTE muta-
tions reduce binding to the low-affinity FcγRs (i.e. hFcγRIIa,
hFcγRIIb, hFcγRIIIa) by more than threefold. The LS substitu-
tions have a more modest effect on hFcγR binding, resulting in a
twofold reduction in affinity for hFcγRI and hFcγRIIaH131, and
threefold reduction for hFcγRIIIaV158. In contrast, the affinities of
the DHS-IgG1 for hFcγRs were statistically indistinguishable (or
slightly improved in the case of hFcγRIIIaF158) compared to those
of wt-IgG1 (Table 4, Supplementary Fig. 8a). Class-switched
IgG2, IgG3, or IgG4 variants of Trastuzumab bearing DHS
mutations also showed statistically indistinguishable binding to
hFcγRs relative to their wt counterparts (Supplementary Fig. 8b).
Not surprisingly, the in vitro ADCC activity of DHS-
Trastuzumab IgG1 was identical to that observed with wt Tras-
tuzumab in hFcγRIIIa-V/V and -V/F donors, but greater than
that of YTE-Trastuzumab IgG1 or LS-Trastuzumab IgG1
(Fig. 3a). On the other hand, as expected35, with homozygotic
hFcγRIIIa-F/F donors, DHS-Trastuzumab IgG1 showed equiva-
lent ADCC activities with wt Trastuzumab or LS-Trastuzumab
IgG1 (Fig. 3a).
Next, we examined the ability of anti-CD20 (Rituximab)
antibody variants to activate the classical complement pathway
Table 2 Pharmacokinetic parameters for hemizygotic Tg276 hFcRn transgenic mice
AUCinf. (μg days/mL) Clearance (mL/day) β-phase T1/2 (h) Vss (mL/kg)
wt-IgG1 30.0 ± 1.6 0.66 ± 0.17 49.6 ± 13.4 1.50 ± 0.15
DHS-IgG1 157.9 ± 3.4 0.11 ± 0.01 290.9 ± 25.6 0.59 ± 0.11
YTE-IgG1 96.9 ± 3.3 0.24 ± 0.03 148.4 ± 36.8 0.72 ± 0.14
LS-IgG1 84.4 ± 2.0 0.21 ± 0.03 92.9 ± 6.1 0.60 ± 0.06
Data are presented as mean ± standard deviation (n= 11)
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via the recruitment of C1q. Target cells (CD20+ Raji) opsonized
with DHS-Rituximab IgG1 antibodies had a higher level of cell
surface-deposed C1q relative to wt-, LS-, or YTE-Rituximab
antibodies. DHS-Rituximab displayed twofold more potent CDC
(0.7 ± 0.1 μg/mL) than wt- (1.5 ± 0.1 μg/mL) or LS-Rituximab
(1.9 ± 0.1 μg/mL), and 10-fold more potent CDC than YTE-
Rituximab, the latter which has already been reported to
display significantly lower CDC activity than wt-Rituximab18,48
(Fig. 3b, c).
Rheumatoid factor (RF) refers to auto-antibodies that bind to
the Fc domain of immunoglobulins. The binding of RF to
therapeutic antibodies is associated with faster clearance and
a
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Fig. 2 IgG pharmacokinetics in new knock-in mouse models. a–h Generation of knock-in mice for human FcγRs, FcRn, β2m, IgG1 heavy chain and kappa
light chain constant regions: a humanization of the mouse low-affinity receptor locus; b humanization of the ectodomains of mouse FcγRI; c humanization
of the ectodomains of mouse FcRn; d humanization of the mouse β2m gene (B2m); e breeding strategy to generate Marlene mice; f replacement of the
switch μ region of the mouse heavy chain locus by the constant region of human IgG1 heavy chain (IGHG1); g humanization of the kappa light chain gene
(IGK); h breeding strategy to generate Scarlett mice; a–d, f–g representations are not drawn to scale. Coordinates are based on mouse (GRCm38.p4) and
human (GRCh38.p7) genomic assemblies; mouse genes are in empty rectangles, genomic coordinates are in black; human genes are in solid rectangles,
genomic coordinates are in gray, black triangles represent LoxP sites. mb, exon encoding the transmembrane and intracytoplasmic domains; H, exon
encoding the hinge domain; Neo, selection cassette. Mouse silhouette was created by co-author P.B. i Immunohistochemical localization of hFcRn or
mFcRn in tissue sections of human spleen, and spleen sections from of hFcγRKI mice (VG1543 × VG6074) and Scarlett mice. Scale bar= 200 μm. j hFcγR
expression on different cell populations from the spleen of FcγRnull (negative control), hFcγRKI (positive control), hFcRnKI hFcγRKI, Marlene and Scarlett
mice. P values by one-way Anova with Tukey’s multiple comparison tests, *P≤ 0.05 and ***P≤ 0.001. k Change in serum IgG concentration following tail
vein administration of 2 mg/kg of antibody in Scarlett (hFcRnKI hβ2mKI hFcγRKI hIgG1, κKI) mice (n= 6). Data are presented as mean ± standard deviation
Table 4 KD values for human FcγRs determined by SPR
KD (μM) FcγRI (×10−3) FcγRIIaH131 FcγRIIaR131 FcγRIIb FcγRIIIaF158 FcγRIIIaV158
wt-IgG1 0.21 ± 0.02 0.22 ± 0.06 1.16 ± 0.25 2.64 ± 0.39 1.17 ± 0.23 0.17 ± 0.04
DHS-IgG1 0.28 ± 0.02 0.27 ± 0.04 0.95 ± 0.02 2.91 ± 0.54 0.48 ± 0.07 0.18 ± 0.03
YTE-IgG 0.29 ± 0.02 0.62 ± 0.18 3.20 ± 0.26 6.24 ± 0.10 4.41 ± 0.93 0.82 ± 0.11
LS-IgG1 0.58 ± 0.12 0.41 ± 0.30 1.21 ± 0.02 2.25 ± 0.03 0.64 ± 0.09 0.52 ± 0.09
All IgG variants analyzed with monomeric Fc receptors and their kinetic values were analyzed by the equivalent binding model. Data are presented as mean ± standard deviation from triplicate experiments
0
20
40
0
20
40
0
20
40
N.S.
a b
0
3
6
9
0.1 1 10 100
M
FI
 (×
 10
3 )
wt-Rituximab
YTE-Rituximab
DHS-Rituximab
LS-Rituximab
Isotype control
c
0
30
60
90
120
0.001 0.1 10
CD
C 
(%
)
Antibody concentration (μg/mL)Antibody concentration (μg/mL)
wt-Rituximab
YTE-Rituximab
DHS-Rituximab
LS-Rituximab
Isotype control
wt
-lg
G1
YT
E-l
gG
1
DH
S-l
gG
1
LS
-lg
G1
wt
-lg
G1
Rit
ux
im
ab
Inf
lixi
ma
b
De
no
su
ma
b
YT
E-l
gG
1
DH
S-l
gG
1
LS
-lg
G1
Iso
typ
e c
on
tro
l
wt
-lg
G1
YT
E-l
gG
1
DH
S-l
gG
1
LS
-lg
G1
Iso
typ
e c
on
tro
l
wt
-lg
G1
YT
E-l
gG
1
DH
S-l
gG
1
LS
-lg
G1
wt
-lg
G1
YT
E-l
gG
1
DH
S-l
gG
1
LS
-lg
G1
wt
-lg
G1
YT
E-l
gG
1
DH
S-l
gG
1
LS
-lg
G1
Iso
typ
e c
on
tro
l
AD
CC
 (%
)
F/F donorV/F donorV/V donor
4 μg/mL
10 μg/mL
0.2 μg/mL
0.04 μg/mL
0.008 μg/mL
0.8 μg/mL 0.16 μg/mL
N.S. N.S.
N.S. N.S.
N.S.
N.S.
e
Pl
as
m
on
 s
hi
ft 
(nm
)
f
0
10
20
0 30 60 90 120
wt-IgG1
YTE-IgG1
DHS-IgG1
LS-IgG1
So
lu
bl
e 
ag
gr
eg
at
es
 (%
)
Time (h)
0
10
20
30
40
Ab
so
rb
an
ce
 a
t 4
50
 n
m
d
0
1
2
3
Normal human serum RF+ serum
N.S.
Fig. 3 Features of DHS Fc variants relevant to therapeutic antibody development. a ADCC assay of SK-BR-3 with PBMCs from FcγRIIIa V/V, V/F, or F/F donors.
b C1q deposition on CD20+ Raji cells revealed by flow cytometry. c CDC assay of Rituximab-Fc variants with Raji cells as a function of antibody concentration.
d Binding to rheumatoid factor (RF) measured by ELISA. P values by two-way ANOVA test, NS P≥0.05, *P≤0.05, **P≤0.01, ***P≤0.001, and ****P≤0.0001.
e Extent of antibody aggregation following thermal stress (50 °C incubation) of Trastuzumab variants, measured by size exclusion chromatography (SEC).
f Antibody self-association properties measured by affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) assay. Data are from one experiment
representative of three experiments using three individual donors (a–d). Errors in all plots and tables represent standard deviations from triplicate experiments
Table 3 Pharmacokinetic parameters for Scarlett (hFcRnKI hβ2mKI hFcγRKI hIgG1, κKI) mice
Cmax (mg/mL) AUCinf (μg days/mL) Clearance (mL/day) β-phase T1/2 (h) Vss (mL/kg)
wt-IgG1 29.9 ± 9.2 74.8 ± 7.35 0.27 ± 0.03 92.1 ± 12.3 0.65 ± 0.04
DHS-IgG1 45.6 ± 18.4 356.8 ± 16.7 0.056 ± 0.003 381.0 ± 85.0 0.25 ± 0.01
YTE-IgG1 35.5 ± 11.6 238.1 ± 15.9 0.084 ± 0.006 236.8 ± 20.8 0.33 ± 0.02
LS-IgG1 40.2 ± 12.6 223.0 ± 24.1 0.090 ± 0.009 255.0 ± 31.8 0.36 ± 0.02
Data are presented as mean ± standard deviation (n= 6)
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increased antigen presentation and anti-drug antibodies53–56. We
measured the RF binding of the wt-, DHS-, YTE-, and LS-IgG1 by
ELISA using polyclonal sera from donors with high RF titers.
DHS-IgG1 showed binding to RF sera that was indistinguishable
from that of wt-IgG1 and significantly lower than that observed
with YTE-IgG1 and especially with LS-IgG1 (Fig. 3d).
Size exclusion chromatography (SEC) showed that for all four
IgG subclasses, introduction of the DHS mutations did not affect
protein solubility nor did it lead to soluble aggregate formation
(Supplementary Fig. 9a). The thermodynamic stability of
therapeutic antibodies is one of the most important biophysical
properties for clinical development34,57,58. The melting tempera-
ture (Tm) was comparable for the wt, DHS, and LS35 Fc variants
(Table 5) but was more than 6 °C lower for the YTE variant
(Table 5)34. The susceptibility of the antibody variants to
aggregation at 70 °C was very high for YTE-IgG1, leading to
visible precipitates within minutes, intermediate for LS-IgG1, and
minimal for wt- and DHS-IgG1 (Supplementary Fig. 9b–e).
Similarly, the YTE- and LS-IgG1 formed higher levels of soluble
aggregates upon prolonged incubation at 50 °C (Fig. 3e). Finally,
the self-association propensity of the various engineered Fc
antibodies at room temperature was determined by affinity-
capture self-interaction nanoparticle spectroscopy (AC-SINS), a
widely used assay for antibody developability58–60. Earlier AC-
SINS analyses using 137 FDA-approved antibody drugs found
that AC-SINS plasmon shifts >11.8 nm correspond to antibodies
with high levels of self-association and which represents a
development risk58. For DHS-IgG1 the AC-SINS plasmon shift
was only 0.1 ± 0.5 nm; of note, YTE- and LS-antibodies also
showed low plasmon shift in this assay albeit higher than that of
DHS-IgG1 (Fig. 3f).
Discussion
An ideal Fc domain for therapeutic applications must confer
optimal pH-dependent binding to hFcRn to achieve very long
circulation half-life, maintain intact effector functions, and dis-
play favorable biophysical properties suitable for clinical
development57,58. To enable maximal antibody circulation half-
life, an Fc domain should resemble a pH toggle switch with a low
FcRn KD,pH5.8 and no detectable binding activity at pH 7.4.
However, despite extensive efforts, engineering Fc domains with a
lower FcRn KD,pH 5.8 and no detectable binding at pH 7.4 under
high avidity conditions had proven elusive11,20. Here, we used a
two-step high-throughput screening strategy to isolate the DHS
Fc variant, which has a fivefold lower KD,pH5.8 for FcRn relative to
wt-IgG1 Fc and no detectable binding at pH 7.4. Unlike anti-
bodies containing the YTE or LS half-life extension mutations,
the DHS Fc domain does not bind to high densities of immobi-
lized hFcRn at pH 7.4 (Fig. 1b, c, Table 1). We found that, by
virtue of the lack of detectable binding at pH 7.4 and despite
having a lower affinity for FcRn at endosomal pH relative to the
LS or YTE variants, DHS antibodies exhibit even more favorable
pharmacokinetics in multiple mouse models. Specifically, as
shown in Fig. 1d and Table 2, the DHS Fc domain confers sig-
nificantly improved antibody PK properties relative to the YTE
and LS variants in hemizygous Tg276 mice, a widely used model
for antibody PK studies37. In the Tg276 model, hFcRn is tran-
scribed from the CAG promoter, resulting in ubiquitous high-
level gene expression36. A second transgenic mouse line, Tg32, in
which hFcRn is under the control of the human hFcRn promoter,
is also commonly used for antibody PK studies46; however, in this
model the transgene is inserted in close proximity to a mouse
enhancer region which in turn impacts transcription and tissue-
specific expression. Because neither model fully recapitulates
mouse endogenous FcRn expression38, we constructed new
models in which hFcRn and hβ2m are expressed from the
respective mouse promoters. The binding of antibodies to FcγRs,
and in particular to FcγRs expressed by liver-resident cells, is
known to affect antibody clearance41,42. However, since human
antibodies bind to mouse FcγRs with very different affinities than
those of their human counterparts61,62, the effect of FcγR-
mediated clearance of human IgG cannot be properly accounted
for in animals expressing murine IgG receptors. To address this
shortcoming, we further engineered hFcRnKI hβ2mKI mice to also
express all the human FcγR family proteins (Marlene mice). Yet
another factor that plays an important role for therapeutic anti-
body PK is the competition for hFcRn binding by endogenous,
circulating human IgG. Because mouse IgG does not bind to
hFcRn40 in some earlier antibody PK studies in Tg276 or Tg32
hFcRnTg mice intravenous co-administration of IgG (IVIG) was
attempted as a surrogate for endogenous IgG competition.
However, the effect of IVIG was reported to be dependent on the
mouse model and was more pronounced in animals expressing
lower hFcRn levels40,63. To overcome these problems, we further
engineered the Marlene mice to express chimeric mouse-human
IgG1 containing the constant regions of human IgG1 heavy chain
and human kappa light chain. The resulting Scarlett mouse strain
displayed circulating human IgG1 concentrations comparable to
those of mouse IgG1 in C57BL/6J mice. We note however that
even though the Scarlett model produce levels of human IgG1
comparable to what is physiologically relevant for mouse IgG1, it
may nonetheless somewhat underestimate the impact of com-
peting IgG1 in humans due to species differences since humans
produce higher levels of this antibody isotype. Beyond their utility
in comparing the PK of different half-life extension variants as
shown here, these new knock-in models are likely to prove par-
ticularly useful for preclinical studies for the understanding of
antibody effector functions in mice that express physiologically
relevant levels of hFcγRs and additionally express competing
endogenous IgG1.
Consistent with the improved PK properties of antibodies with
the DHS mutations compared to antibodies with the clinical-stage
YTE and LS variants in Tg276 hemizygous mice in Fig. 1d and
Table 2, the DHS amino acid substitutions resulted in ≥50%
increase of β-phase T1/2 and AUCinf in the Scarlett model. The
relative improvement in the PK parameters of DHS antibodies
compared to the YTE or LS variants in the Scarlett model was
lower than the effect (twofold) observed in Tg276 and may be due
to competition by IgG, the impact of effector FcγR clearance
mechanisms and possibly, mouse strain background differences.
If, as expected, the PK behavior of antibodies in Scarlett mice
more closely mimics that in humans, the observed 50% greater β-
phase half-life and drug exposure afforded by the DHS mutations
should result in significant therapeutic benefit. For example, a
50% improvement over YTE antibodies28 could be expected to
translate into a circulation half-life in humans of well over
100 days.
Table 5 Tm measurement by differential scanning
fluorimetry (DSF)
Tm (°C)
wt-Fc 69.0 ± 0.2
DHS-Fc 70.2 ± 0.2
YTE-Fc 62.4 ± 0.2
LS-Fc 67.9 ± 0.2
Data are presented as mean ± standard deviation (n= 3)
Lee et al. report an engineered IgG1 Fc domain that behaves like an hFcRn binding pH toggle
switch. The authors show that this new half-life extension Fc domain confers improved
pharmacokinetics in new humanized knock-in mouse strains that recapitulate the key processes
for antibody persistence in circulation
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To quantitatively explore the significance of endosomal
retention (determined by KD at pH 5.8) versus surface recapture
(determined by the KD at pH 7.4) we constructed a simple phe-
nomenological PK model (Supplementary Fig. 10). This model is
sufficient to explain the relative PK properties of each Fc domain.
Sensitivity analysis indicates that surface recapture is the domi-
nant parameter limiting circulation persistence of YTE- and LS-
IgG1 mutants. Specifically, in the hemizygotic Tg276 mice as well
as in the Scarlett mice, the consequence of residual affinity of
these Fc domains at the extracellular pH is roughly 50% or 20%
recapture, respectively, of antibody on the cell surface during
endosomal recycling. Collectively, both experimental PK com-
parison and the quantitative modeling of antibodies with distinct
hFcRn-binding properties at endosomal and physiological pH
highlight the negative effect of hFc:hFcRn binding at pH 7.4 on
antibody circulation persistence.
Fc-mediated effector functions (ADCC and CDC), develop-
ability (biophysical properties including thermodynamic stabi-
lity), and drug bioavailability (serum half-life/AUCinf) are of
critical importance for clinical application of therapeutic
antibodies58,64. We demonstrate herein that the DHS Fc variant
has (i) intact Fc-mediated effector functions, (ii) a similar Tm,
low aggregation propensity, no evidence for self-association and
low binding to RF, similar to wt IgG1 antibodies, and (iii) ultra-
long circulation persistence in highly relevant new humanized
mouse models.
Methods
Cells and reagents. Adenocarcinoma SK-BR3 cell line (ATCC® HTB-30™) and
Raji cell line (ATCC® CCL-86™) were obtained from American Type Culture
Collection. SK-BR3 was cultured in complete Dulbecco's modified Eagle's medium
(DMEM) with 10% fetal bovine serum (FBS) and Raji was cultured in complete
RPMI 1640 with 10% FBS. Human PBMCs were purified from anonymous healthy
volunteers using histopaque density gradient centrifugation (Sigma-Aldrich).
Human C1q (CompTech) and hFcRn:hβ2m (Novus Biologicals) were purchased.
All primers were synthesized by Integrated DNA Technologies.
Preparation of recombinant proteins. Human Fc receptors, including hFcγRI,
hFcγRIIa, hFcγRIIb, hFcγRIIIa, and hFcRn:hβ2m, were cloned in-frame into the
mammalian expression vector pcDNA3.4 using Gibson Assembly cloning (NEB)44
and were produced by transient transfection of Expi293 cells (Invitrogen)
according to the manufacturer’s instruction43,44,65. His-tagged Fc receptor proteins
were purified with Ni-NTA (GE Healthcare) affinity columns and GST-tagged Fc
receptor proteins were purified with Glutathione Sepharose (GE Healthcare) affi-
nity columns according to the manufacturer’s instructions. In order to remove
lipopolysaccharide (LPS) and non-specifically bound protein, the Fc receptor-
bound resins were washed with 50 mL of PBS containing 0.1% Triton®X-114
(Sigma-Aldrich) and 50 mL of PBS. His-tagged Fc receptor proteins were eluted
with PBS containing 250 mM imidazole and GST-tagged Fc receptor proteins were
eluted with PBS containing 10 mM reduced L-glutathione. The buffer in the Fc
receptor protein containing eluent fraction was exchanged with PBS by Amicon
Ultra-30 centrifugal spin columns (Milipore).
Similarly, isolated Fc candidates were cloned in-frame into the mammalian
expression vector pcDNA3.4-IgH-Trastuzumumab using Gibson Assembly cloning
(NEB)66 and were produced in Expi293 cells (Invitrogen) grown for 5 days at 37 °C
with 8% CO2. All IgG variants proteins purified by Protein A high capacity agarose
resin (Thermo Scientific) according to the manufacturer’s instructions. Purity of
antibody variants was confirmed by SDS-PAGE and size exclusion
chromatography and was over 95%.
Library construction and screening. Amino acid residues D249-R255, V308-
L314, and E430-Q438 in the Fc that are within 7 Å distance from FcRn in the
crystal structure of the human Fc:FcRn complex (PDB ID: 4N0U)13 were selected
for mutagenesis using the aa substitution scheme shown and three separate
libraries were constructed using primers with degenerate codons (Supplementary
Table 1). The heavy chain of trastuzumab IgG1 was used as the template. The
amplified PCR fragments were ligated into pPelB-AglycoT(H)-FLAG43 with SfiI
restriction sites for the histidine scanning library. The resulting plasmids were
transformed into E. coli Jude-1(F′ [Tn10(Tetr) proAB+ lacIq Δ(lacZ)M15] mcrA Δ
(mrr-hsdRMS-mcrBC) 80dlacZΔM15 ΔlacX74 deoR recA1 araD139 Δ(ara leu)7697
galU galK rpsL endA1 nupG) harboring pBAD-AglycoT(L)-His43,67 to display both
heavy and light chain of aglycosylated IgG1 in periplasm anchored on the inner
membrane via the NlpA signal peptide (APEx display)45. Following electroporation
1 × 108 transformants were obtained. The transformants were spheroplasted after
overnight induction with 1 mM of IPTG and 0.2% of L-arabinose, followed by
screening with 10 nM of hFcRn:hβ2m, conjugated with fluorescent Alexa488
(hFcRn:hβ2m Alexa488) as a target probe, at pH 5.8 in PBS. Screening was per-
formed using a FACSAria™ (BD Biosciences). In each round, the top 3% of the
population showing the highest fluorescence was collected and the spheroplasts
were re-sorted immediately to remove false positives. The transformants with the
plasmids of sorted spheroplasts were prepared. After four rounds, in order to
achieve pH-selective binding activity, the library was first labeled with 5 nM of
GST-hFcRn:hβ2m-Alexa647 at neutral pH, then incubated with 10 nM of hFcRn:
hβ2m-Alexa488 at pH 5.8 (Fig. 1a). After the fifth round, single Fc variants were
analyzed with pH-dependent-binding activities by flow cytometry and the four
candidates were isolated.
LC-ESI-MS/MS analysis of Fc variants. Fc proteins were analyzed by The Uni-
versity of Texas at Austin Proteomics Facility using LC-MS on Thermo Orbitrap
Fusion Tribrid mass spectrometer with the FT detector. A fast gradient of 0.1%
formic acid/water and 0.1% formic acid/acetonitrile over 10 min was used to elute
the intact proteins from an OPTI-TRAPTM protein microtrap (Optimize Tech-
nologies). The Orbitrap Fusion was operated in Intact Protein Mode at 15,000
resolution from 400 to 2000m/z. The data were deconvoluted using Thermo
Protein Deconvolution software.
Size exclusion chromatography. SEC analyses for the purified IgG proteins were
performed on an ÄKTA Pure (GE Healthcare) liquid chromatography system
using a Superdex 200 10/300GC, (GE Healthcare), with a mobile phase of pH 7.4
PBS at a flow rate of 0.75 mL/min. Chromatograms were obtained by monitoring
the absorbance at 280 nm. The injection amount was 100 μg of proteins in a
volume of 200 μL. For thermal stress test, each antibody protein (1 mg/mL) was
incubated at 70 °C for 10, 20, 40, and 60 min and then analyzed by SEC using the
above described method.
Differential scanning fluorimetry. Differential scanning fluorimetry (DSF) was
performed with SYPRO Orange dye (Catalog #S-6650; Life Technologies) to
determine the thermal stability by monitoring the protein unfolding of the purified
Fc domains. For each sample, 15 μL of Fc domains varying from 0.08 to 20 μM
were mixed with 5 μL of dye, diluted from 5000× to 20× for use. Each experiment
included a control without proteins containing 100 mM HEPES buffer at pH 7. The
DSF assays were performed on an Applied Biosystems ViiA 7 Real-Time PCR
System using a temperature gradient from 25 to 99 °C at a temperature ramp rate
of 0.03 °C/s. The fluorescence emissions and melting temperature measurements
were analyzed using ViiA 7 Software from Life Technologies.
AC-SINS. Goat anti-human Fc fragment specific (Jackson ImmunoResearch, 109-
005-008) was buffer exchanged into 20 mM potassium acetate (pH 4.3) twice using
Zeba desalting columns (Thermo Fisher Scientific, PI-89882). The goat anti-human
Fc concentration was evaluated using UV absorbance value at 280 nm (extinction
coefficient of 1.26 mL/mg cm). The polyclonal antibody was diluted to 0.4 mg/mL
in the acetate buffer. Equal volumes of goat anti-human Fc antibody and gold
nanoparticles (Ted Pella, 15705-1) were incubated at room temperature (1 h). The
antibody-gold conjugates (3 mL) were loaded onto 0.22 μm filters (Millipore Sigma,
SLGV013SL, PVDF), resulting in the retention of the conjugates on the filter
membrane. PBS buffer (150 μL) was added to the filter cartridges to elute the gold
conjugates, which typically resulted in recovery of ~100 μL per cartridge. The
concentrated conjugates were mixed well by pipetting up and down ten times. The
conjugates (5 μL) were added first to a 384-well polystyrene plate (Thermo Fisher,
12-565-506), and then the PBS control or test antibodies (in PBS, 45 μL) were
added. The samples were mixed well by pipetting up and down ten times. The
absorbance spectra were measured (450–650 nm) in 1 nm increments using a
Biotek Synergy Neo microplate reader (BioTek, Winooski VT). The plasmon
wavelengths were calculated by fitting a second order polynomial equations to the
40 absorbance measurements surrounding the maximum absorbance values and
setting the first derivatives of the polynomials to zero. The plasmon shifts were
calculated as the difference in the plasmon wavelengths of the test antibodies
relative to the PBS control (no human antibody).
hFc:hFcRn KD determination using surface plasmon resonance. For SPR
analysis, IgG1 antibody variants were immobilized on CM5 chip surface at a
density of ~500 response units (RU) via an amine coupling. hFcRn:hβ2 m dimer
(Novus Biologicals) was injected at serially diluted concentrations (1000–40 nM) in
PBS, pH 5.8, at a flow rate of 30 μL/min. To examine the interaction of hFcRn and
antibody variants at physiological pH 7.4, hFcRn:hβ2m dimer (Novus Biologicals)
was immobilized on the BIACore Chip at three different densities, 500 RU, 2000
RU, and 4000 RU via amine coupling11. Serially diluted antibodies (800–50 nM)
were injected in PBS, pH 7.4, at a flow rate of 30 μL/min. Dissociation constants
(KDs) were determined by fitting the corresponding binding isotherms for steady-
state data or by fitting the kinetics for association and dissociation employing a 1:1
Langmuir mass transfer model. In addition, to detect the function of pH for hFc:
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hFcRn interaction, 800 nM of each antibody variants was injected under diverse pH
conditions (pH 6.0–8.0) and RUmax was measured.
ELISA assays. Fifty microliters of 2 μg/mL antibody variant was diluted in PBS
(pH 7.4) and used to coat a 96-well polystyrene ELISA plate (Corning, Corning,
NY) overnight at 4 °C. After blocking with PBS (pH 7.4) with 3% bovine serum
albumin (BSA) for 1 h at room temperature, the plate was washed four times with
PBS containing 0.05% Tween-20 (PBST) and incubated with serially diluted GST-
hFcRn:hβ2m, His-tagged hFcγRI, GST-tagged hFcγRIIa, GST-tagged hFcγRIIb, or
GST-tagged hFcγRIIIa in PBS (pH 7.4) at room temperature for 1 h. After washing
four times with PBST, either 1:10,000 diluted HRP conjugated anti-His or anti-GST
antibody (Rockland Immunochemicals) was added, and plates were washed with
PBST. Absorbance at 450 nm was measured after development with TMB substrate
(Pierce Biotechnology, Rockford, IL) according to the manufacturer’s instructions.
RF-binding assays. Fifty microliters of RF positive serum (Lee Biosolutions),
obtained from three different RA patients, was coated in a 96-well polystyrene
ELISA plate (Corning, NY) overnight at 4 °C. After a blocking and washing step,
plates were incubated with biotinylated antibody variants for 1 h at room tem-
perature. The binding was detected by streptavidin-HRP and TMB substrate
(Thermo Fisher Scientific) according to the manufacturer’s instructions.
ADCC assays. Her2-overexpressing SK-BR3 breast cancer cells were cultured in
complete DMEM and collected by centrifugation at 300 × g for 5 min. The har-
vested SK-BR-3 cells were washed in PBS and labeled with 4 μM Calcein AM (Life
Technologies, USA) in PBS at 37 °C under 5% CO2 for 30 min. The Calcein-loaded
SK-BR-3 cells were washed twice, resuspended in RPMI medium, and seeded into a
96-well plate at 10,000 cells/well. The various concentrations of IgG variants were
also added. PBMCs were isolated from human blood from healthy donors. Briefly,
50 mL of human blood was collected in heparinized vials (BD Biosciences) and
mixed by gently inverting the tube several times. Twenty-five microliters of blood
was layered over 25 mL of Histopaque (Sigma-Aldrich) in 50 mL conical tubes. The
tubes were centrifuged at 400 × g for 10 min in a swing-out bucket with no brakes.
The human PBMCs were aspirated in the interphase between histopaque and
medium. Human PBMCs were resuspended with red blood cell (RBC) lysis buffer
(155 mM NH4Cl, 12 mM NaHCO3, and 0.1 mM EDTA), and washed twice with
PBS. PBMCs were transferred into a 96-well plate at 100,000 cells/well (the ratio of
tumor versus PBMCs was 1:10), and the plates were incubated at 37 °C under 5%
CO2 for 4 h. The released calcein AM was detected at excitation and emission
wavelengths of 485 and 535 nm. The percent of tumor cell lysis was calculated
according to the following formula:
100 ´ E  Sð Þ ´ M  Sð Þ1; ð1Þ
where E is the fluorescence of experimental well, S is the fluorescence of a well
containing tumor cells and complement but no antibody, and M is the fluorescence
of a well containing tumor cells with lysis buffer (Triton X-100 at 2% v/v, SDS 1%
w/v, 100 mM NaCl, and 1 mM EDTA). As an isotype control, Rituximab was used.
C1q deposition assay. Raji cells were resuspended in 25% human serum and then
incubated with the serially diluted Rituximab-Fc variants at 37 °C for 30 min.
Classical complement activation reactions were then quenched with 20 volumes of
ice-cold 1% BSA-PBS. The cells were pelleted, washed once, and then probed with
FITC anti-C1q (Abcam) for 30 min at 4 °C. The samples were washed and analyzed
by flow cytometry.
CDC assay. For CDC assay, Raji cells were labeled with 4 μM Calcein AM (Life
Technologies, USA) in PBS at 37 °C under 5% CO2 for 30 min and serially diluted
Rituximab variants were incubated with 25% human serum and calcein AM-loaded
Raji cells at 37 °C for 1 h in 96-well plates. The supernatants were collected after
centrifugation at 1000 × g for 10 min. The fraction of lysed Raji cells was deter-
mined by the same method as used for the ADCC assays. As an isotype control,
Trastuzumab was used.
Mice. Hemizygous hFcRn transgenic mice (line 276; aka Tg276) were generated by
the F1 cross of murine FcRn-deficient B6.129X1-Fcgrttm1Dcr/DcrJ and hFcRn
transgenic line (generated by random integration of the hFcRn cDNA) B6.Cg-
Fcgrttm1Dcr Tg (CAG-FCGRT) 276 Dcr/DcrJ (The Jackson Laboratory)5,68. Tg276
mice experiments were performed under a protocol approved by UT Austin
institutional Animal Care and Use Committee (IACUC). hFcγRKI mice51 were
generated by Regeneron Pharmaceuticals Inc. to express hFcγRI, hFcγRIIaH131,
hFcγRIIbI232, hFcγRIIcstop13, hFcγRIIIaV158, and hFcγRIIIbNA2 polymorphic var-
iants, as described previously51. hFcRnKI (VG1481) and hβ2mKI (VG5153) were
designed and generated by Regeneron Pharmaceuticals Inc. on a mixed 62.5%
C57BL/6N and 37.5% 129S6/SvEv genetic background. hIgG1-heavy chainKI
(hIgG1KI) were generated on a BALB/c background in the Cogné lab. Human
kappa-light chainKI (IgκKI) were generated on a C57BL/6N background in the
Bruhns lab. Mice were intercrossed at Institut Pasteur (Bruhns lab) to generate
Marlene (hFcRnKI hβ2mKI hFcγRKI) or Scarlett (hFcRnKI hβ2mKI hFcγRKI hIgG1,
κKI) mice and used for experiments at 10–18 weeks of age. FcγRnull mice expressing
no FcγRs were used as controls. All mouse models demonstrated normal devel-
opment and breeding patterns and hFcγR expression on different cell populations
from the spleen were confirmed, as described previously51.
Experiments using knock in mice were validated by the Comité d'Éthique en
Expérimentation Animale (CETEA) #89 (Institut Pasteur, Paris, France) under
#2013-0103 and by the French Ministry of Research under agreement #00513.02.
Endogenous mouse or human IgG detection in knock-in mice. Goat anti-human
IgG-Fc fragment antibodies (1 μg) or goat anti-mouse IgG-Fc fragment anti-
bodies (0.2 μg) were diluted in carbonate buffer (pH 9.6) (Bethyl Laboratories,
Montgomery, TX) and used to coat MaxiSorp 96-well ELISA plates (Nunc,
ThermoFischer scientific, Waltham, MA) overnight at 4 °C. After blocking with
PBS with 3% BSA for 1 h at room temperature, plates were washed three times
with PBST and incubated with serially diluted wt or KI mouse serum (or human
and mouse reference serum as quantification standards), at room temperature for
3 h. After washing, HRP-conjugated anti-human IgG (diluted 1:20,000; Bethyl
Laboratories Inc.) or anti-mouse IgG (diluted 1:10,000; Bethyl Laboratories Inc.)
were added, and plates were washed with PBST. Absorbance at 492 vs 620 nm
was measured after development with the OPD substrate (Sigma Aldrich, Saint-
Louis, MO).
Immunohistochemistry. Spleens were fixed in 10% neutral-buffered formalin for
24 h and embedded in paraffin. Tissue sections (4 μm) were blocked in PBS con-
taining 3% BSA. Sections were stained with either an anti-human FcRn antibody
(4 μg/mL, Novus Biologicals) or an anti-mouse FcRn antibody (100×; R&D Sys-
tems) for 30 min at 37 °C. Primary antibodies were detected with appropriate
peroxidase-conjugated secondary antibodies and DAB detection kit (<8 min, RT).
All staining reactions were accompanied by a negative control that consisted of an
isotype-matched irrelevant antibody. Stained slides were evaluated with a light
microscope (Nikon).
RT PCR. Total RNA was extracted from human peripheral blood mononuclear
cells or murine splenocytes using NucleoSpin RNA plus kit (Macherey-Nagel)
according to the manufacturer’s recommendations. cDNAs were generated at 50 °C
for 60 min using random primers and SuperScript III Reverse Transcriptase
(Invitrogen). The primer pairs for the human FcRn gene FCGRT (L28-L179) and
the mouse FcRn gene Fcgrt (L231-R295) (FCGRT: 5′-CTCTCCCTCCTGTACCA
CCTT-3′; 5′-ATAGCAGGAAGGTGAGCTCCT-3′; Fcgrt: 5′-AGCTCAAGTTCCG
ATTCCTG-3′; 5′- GATCTGGCTGATGAATCTAGGTC-3′) were used for
amplification with GoTaq G2 polymerase (Promega). Amplification was performed
by 35 cycles PCR each consisting of 94 °C for 1 min, 58 °C for 1 min, and 72 °C for
1 min. At the end of the 35 cycles, samples were run for an additional 10 min at 72 °
C and analyzed by 1.5% agarose gel electrophoresis.
Pharmacokinetics studies in mice. Animals were administered a bolus intrave-
nous (i.v.) dose of 2 mg/kg antibody on day 0 by tail vein injection. Blood samples
were obtained from the tail vein using capillary pipettes at different time points.
Serum concentration of antibody in Tg276, Marlene, or Scarlett was determined
using a quantitative ELISA as follows: 96-well plates were coated with 2 μg of Goat
anti-human F(ab′)2 fragment-specific F(ab′)2 (for Tg276; Jackson
Immunoresearch) or 1 μg of each antigens (for Marlene and Scarlett). Her2
extracellular domain protein (Antibodies-Online) for trastuzumab, CD20 linear
peptide (142–184, extracellular domain; Alpha Diagnostic Intl., Inc.) for rituximab,
or IgE protein for omalizumab was used. Plates were blocked with 1% Fish gelatin
(AMRESCO Inc) in PBS for 1 h, and then incubated with appropriately diluted
serum samples (1:200 for earlier time points and 1:50 or 1:100 for later time
points). Anti-kappa light chain antibody-HRP (Abcam) was used to detect the
human antibody (dilution 1:5,000). Absorbance at 450 nm was measured after
development with TMB substrate (Pierce Biotechnology, Rockford, IL) according
to the manufacturer’s directions. Standard curves were generated for each antibody
variant diluted into 1:100 pre-bleed mouse serum. The linear portions of standard
curves generated in Prism (GraphPad Software) were then used to quantify human
IgG in the serum samples.
Pharmacokinetic parameters were analyzed with a two-compartment
elimination model. AUCinf (area under the curve to infinity) was calculated using
the log-linear trapezoidal method20. Terminal half-life (T1/2) was calculated using
two-phase clearance models. Log-linear regression of the concentration data
including at least the last six sampling time-points with measurable concentrations.
Serum clearance was estimated as
CL ¼ DoseAUC1inf : ð2Þ
Volumes of distribution at steady state were calculated using the following
equation:
Vss ¼ Dose ´AUMCinf ´ ðAUCinf Þ2: ð3Þ
Computational modeling. All analysis was implemented in R and Stan, and
can be found at [https://github.com/meyer-lab/FcRn-trafficking], release 1.0
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(https://doi.org/10.5281/zenodo.3474026). Test conditions were identified
throughout to ensure model accuracy.
Exogenous IgG trafficking was modeled according to the following
relationships, consistent with the graphic presented in Supplementary Fig. 10.
Exogenous IgG is modeled to exchange between three compartments representing
a central extracellular, peripheral extracellular, and endosomal space. The central
compartment is modeled as
δCc
δt
¼ QðCp  CcÞ; ð4Þ
where Cc, Cp, and Ce indicate the central, peripheral, and endosomal compartment
concentrations, respectively, in units of μg/mL. Q indicates the transport rate
between these two compartments in units of the central compartment volume per
hour. As the entire model scales proportionally, the central compartment volume
(Vc) was assumed to equal 1, and all volumes are specified in relative amounts. The
peripheral compartment concentration was specified as
δCp
δt
Vp ¼ QCc  QCp  QuCp þ QuCefsortfrelease; ð5Þ
where Vp and Ve are the peripheral and endosomal volumes (relative to the central
compartment volume), and Qu is the rate of uptake into cells in units of central
compartment volume per hour.
fsort indicates the fraction of endosomal IgG that is recycled, and frelease indicates
the fraction of IgG presented to the cell surface that is released (as opposed to
endocytosed again).
δCe
δt
Ve ¼ Qu Cp þ Ce ð1 freleaseÞfsort  1½ 
h i
: ð6Þ
Implicit in this model are a few assumptions: First, there is no clearance outside of
cellular uptake and lysosomal degradation. Each sorting fraction and model
parameter is assumed to not vary with the concentration of exogenous IgG,
therefore assuming that the modeled processes are not saturable. Finally, sorting
and release are assumed to vary in the same order as their measured affinities at pH
5.8 and 7.4, with IgG of no measurable affinity at 7.4 fully released (frelease= 1).
The resultant linear ODE model was solved using the matrix exponential of the
Jacobian. The half-life was found through root finding with Newton’s method.
Model fitting was performed using Markov Chain Monte Carlo within Stan69.
Priors on Vp, Q, and Vin were all specified as log-normal distributions with a mean
and deviation of 1 in their respective units. The prior for Qu was specified as a log-
normal distribution with mean e0.1 and deviation of 0.5. Sorting parameter priors
were specified to be flat and constrained to be in the order dictated by their relative
affinity measurements. For example, if species A had a higher endosomal affinity
than B, then fsort,A was given an even prior from 0 to 1, and sort,B was given an even
prior from 0 to fsort,A. The half-life of each species was compared to a normal
distribution representing the average and standard error of the in vivo
experimental measurements. Sampling convergence was verified through
autocorrelation analysis and the Geweke criterion.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All the other data that support the findings of this study are available from the
corresponding author upon request.
Code availability
All analysis for computational modeling was implemented in R v3.5.3 and rstan
v2.18.2, and can be found at [https://github.com/meyer-lab/FcRn-trafficking], release 1.1
(https://doi.org/10.5281/zenodo.3474026). The code is available for access under the MIT
license without restrictions.
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